ArticleBrain & spine2026
Medical treatment of osteoporosis in osteoporotic vertebral fractures - Results from the prospective EOFTT multicenter study.
Article in Brain & spine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Osteoporotic medication (oTh) is essential for secondary prevention but is often not prescribed after vertebral fractures. Research question: The aim of this analysis was to assess the status of oTh in inpatients with osteoporotic thoracolumbar fractures and to analyze possible supply gaps. Materials and methods: Data were collected as part of the multicenter, prospective EOFTT (Evaluation of the Osteoporotic Fracture Classification, Treatment Score and Therapy Recommendations) study. A total of 518 patients with osteoporotic thoracolumbar fractures in 17 clinics were included. The presence, type, and changes over time of oTh were recorded and evaluated using the Cochrane Q test. Results: Hospitalisation increased oTh with 36% at admission significantly in women to 83%, and in men to 71% (p < 0.001). At admission women received more frequently oTh than men (p = 0.017). At the follow-up after 7 ± 5 months, there was no significant differences between the sexes (p = 0.330). However, the proportion in both groups decreased significantly to 41% (women) and 34% (men), respectively (p < 0.001). In-hospital treatment led to a significant increase in the initiation of anti-osteoporotic medication, with calcium and vitamin D supplementation rising from 13% at admission to 35% at discharge (p < 0.001). However, a substantial and significant decline was observed during follow-up (18%, p < 0.001). Discussion and conclusion: In the inpatient setting, there is a clear improvement in oTh, which is particularly pronounced in female patients. However, the significant decline in therapy rates at follow-up highlights deficits in long-term care. Despite existing recommendations, evidence-based agents such as bisphosphonates or osteoanabolic are still rarely used. This indicates a relevant gap in care in secondary prevention and underscores the need for structured, post-hospitalisation concepts for sustainable osteoporosis therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.